#1 Clinical Trials Search in Europe

Lacutamab

Lacutamab, a promising new drug, is currently being studied in clinical trials for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This article explores the ongoing research on Lacutamab, its potential benefits, and what patients should know about participating in these trials.

Table of Contents

What is Lacutamab?

Lacutamab is a new medication being studied for the treatment of certain types of blood cancers. It is classified as a monoclonal antibody, which is a type of drug that targets specific proteins in the body. In this case, Lacutamab targets a protein called KIR3DL2[1].

What Conditions Does Lacutamab Treat?

Lacutamab is being investigated for the treatment of Peripheral T-Cell Lymphoma (PTCL), particularly in patients whose disease has come back (relapsed) or did not respond to previous treatments (refractory). PTCL is a group of rare and aggressive blood cancers that develop from T-cells, a type of white blood cell important for the immune system[1].

The specific types of PTCL being studied include:

  • PTCL Not Otherwise Specified (NOS): A general category for T-cell lymphomas that don’t fit into other specific subtypes
  • PTCL-TFH: Including Angioimmunoblastic T-cell Lymphoma (AITL), Follicular T-cell lymphoma, and Nodal peripheral T-cell lymphoma with TFH phenotype
  • Anaplastic Large Cell Lymphoma (ALCL): A type of T-cell lymphoma that can affect the skin, lymph nodes, and other organs
  • Adult T-cell Leukemia/Lymphoma (ATL): A rare type of T-cell lymphoma caused by a virus
  • Hepatosplenic T-cell Lymphoma (HSTL): A rare and aggressive type that affects the liver and spleen
  • Enteropathy-associated T-cell Lymphoma (EATL) and Monomorphic Epitheliotropic Intestinal T-cell Lymphoma (MEITL): Types that affect the intestines
  • NK-T cell Lymphoma (NKT) and Aggressive NK-cell Leukemia (ANKL): Rare types involving natural killer cells, another type of immune cell

How Does Lacutamab Work?

Lacutamab works by targeting a specific protein called KIR3DL2, which is found on the surface of cancerous T-cells in many types of PTCL. By attaching to this protein, Lacutamab helps the immune system recognize and destroy the cancer cells[1].

Current Clinical Trial

A clinical trial is currently underway to evaluate the safety and effectiveness of Lacutamab in treating relapsed or refractory PTCL. This trial is a Phase II study, which means it’s testing the drug in a larger group of patients after initial safety studies have been completed[1].

Treatment Regimen

In the clinical trial, Lacutamab is being tested in combination with two other chemotherapy drugs, Gemcitabine and Oxaliplatin (together called GemOx). The treatment plan includes:

  1. Induction phase: Patients receive Lacutamab (750 mg intravenously) along with GemOx for 6 cycles, each cycle lasting 3 weeks (about 4.5 months total)
  2. Maintenance phase: If the treatment is effective, patients continue to receive Lacutamab alone for up to 20 additional cycles, each cycle lasting 4 weeks

The study is comparing this combination treatment to GemOx alone, which is a standard treatment for relapsed or refractory PTCL[1].

Measured Outcomes

The main goal of the study is to measure how long patients live without their disease getting worse, called progression-free survival. Other important outcomes being measured include:

  • Overall survival
  • How many patients respond to the treatment
  • How long the responses last
  • How many patients are able to proceed to stem cell transplantation after treatment
  • The levels of Lacutamab in the blood over time
  • Whether patients develop antibodies against Lacutamab

These measurements will help researchers understand how well Lacutamab works and how safe it is for patients[1].

Potential Side Effects

While the specific side effects of Lacutamab are still being studied, the clinical trial is carefully monitoring for any adverse events. As with any cancer treatment, there may be side effects, which can vary from person to person. Patients in the trial will be closely monitored for any unexpected reactions or complications[1].

Aspect Details
Drug Name Lacutamab
Drug Type Monoclonal anti-KIR3DL2 antibody
Condition Studied Refractory/Relapsing Peripheral T-Cell Lymphoma (various subtypes)
Trial Phase Phase II
Treatment Regimen Lacutamab (750 mg/IV) + Gemcitabine (1000 mg/m²) + Oxaliplatin (100 mg/m²)
Treatment Duration Induction: 6 cycles of 3 weeks (4.5 months)
Maintenance: Up to 20 additional cycles of 4 weeks
Primary Outcome Median modified progression-free survival (mPFS)
Key Secondary Outcomes Overall survival, response rates, safety, pharmacokinetics, immunogenicity

FAQ

  • What is Lacutamab? Lacutamab is a monoclonal antibody that targets KIR3DL2, a protein found on certain types of T-cells. It is being studied as a potential treatment for various types of peripheral T-cell lymphoma.
  • What types of lymphoma are being studied in the Lacutamab clinical trial? The trial is studying various subtypes of peripheral T-cell lymphoma, including PTCL-NOS, PTCL-TFH, anaplastic large cell lymphoma, adult T-cell leukemia/lymphoma, hepatosplenic T-cell lymphoma, and others.
  • How is Lacutamab administered in the clinical trial? In the trial, Lacutamab is given intravenously at a dose of 750 mg, along with other chemotherapy drugs called Gemcitabine and Oxaliplatin.
  • What are the main goals of the Lacutamab clinical trial? The main goals are to evaluate the safety and effectiveness of Lacutamab in combination with other drugs, compared to standard treatment. The trial measures things like how long patients live without their disease getting worse and how many patients respond to the treatment.
  • How long does the Lacutamab treatment last in the clinical trial? The treatment in the trial consists of an induction phase lasting about 4.5 months (6 cycles of 3 weeks each), followed by a maintenance phase where Lacutamab is given for up to 20 additional cycles of 4 weeks each.

Ongoing Clinical Trials on Lacutamab

  • Study of Lacutamab, Gemcitabine, and Oxaliplatin for Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Spain

  • Study of Lacutamab Alone or with Chemotherapy for Patients with Advanced T-Cell Lymphoma

    Not recruiting

    2 1 1
    Investigated drugs:
    Belgium France Germany Italy Poland Spain

Glossary

  • Peripheral T-Cell Lymphoma (PTCL): A group of rare and often aggressive blood cancers that develop from mature T-cells, a type of white blood cell important for immune function.
  • Monoclonal Antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells. In cancer treatment, monoclonal antibodies can be used to deliver drugs directly to cancer cells.
  • KIR3DL2: A protein found on the surface of certain T-cells that Lacutamab targets in its mechanism of action.
  • Refractory/Relapsing (R/R): Refers to cancer that has either stopped responding to treatment (refractory) or has come back after a period of improvement (relapsing).
  • Induction Phase: The initial part of cancer treatment aimed at reducing the amount of cancer in the body.
  • Maintenance Phase: A phase of treatment that follows the induction phase, aimed at preventing the cancer from returning or growing.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives without the cancer getting worse.
  • Overall Response Rate (ORR): The percentage of patients whose cancer shrinks or disappears after treatment.
  • Pharmacokinetics: The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and excreted.
  • Immunogenicity: The ability of a substance to provoke an immune response in the body, which is important to monitor in drug development.

References